Current Approaches to the Diagnosis and Treatment of Polycystic Ovarian Syndrome in Youth
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in reproductive-age women. It often presents during late adolescence but in some cases certain features are evident even before menarche. PCOS is a spectrum of disorders with any combination of oligo/anovulation, clinical and/or biochemical evidence of androgen excess, obesity, insulin resistance and polycystic ovaries on ultrasound. The pathogenesis is unknown; however, it is a complex multigenetic disorder where disordered gonadotropin release, dysregulation of steroidogenesis, hyperinsulinism and insulin resistance play a role. The diagnosis is based on a typical physical exam (acne, hirsutism, obesity, and acanthosis nigricans) and laboratory evidence of hyperandrogenism, such as elevated free testosterone, androstenedione and dehydroepiandrosterone sulfate (DHEAS), decreased sex hormone-binding globulin (SHBG) and increased luteinizing hormone (LH). An ovarian ultrasound may detect the multiple cysts. Secondary causes of PCOS need to be excluded. There are several classes of medications correcting different parameters of PCOS that can be used alone or in combination. Oral contraceptive therapy is used to reduce androgen and LH levels with resultant improvement in acne and hirsutism, and the induction of regular menses. Antiandrogens are usually required for a substantial improvement in hirsutism score. Insulin sensitizers such as metformin are a new class of drugs utilized in treatment of PCOS. By improving insulin sensitivity and decreasing insulin levels, they improve the unfavorable metabolic profile of patients with PCOS. Metformin also helps to increase SHBG, decrease androgen levels and induce ovulation. Despite all the available medications, life-style changes are the mainstay of therapy as weight loss and exercise improve all parameters of PCOS without the potential side effects of medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Moran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Role of Hormones in Pilosebaceous Unit Development
Deplewski, D., & Rosenfield, R. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.4.0404 · Cited by 443 · cited 1×
“Antiandrogens Antiandrogens are usually required to substantially improve the hirsutism score. They act as competitive antagonists of steroid binding to the androgen receptor and reverse the androgen-induced transformation of vellus to terminal hairs [”
BackgroundMcNATTY, K. P., MAKRIS, A., DEGRAZIA, C., RAPIN, O., & RYAN, K. J. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-49-5-687 · Cited by 367
Ibañez, L., Potau, N., Virdis, R., Zampolli, M., Terzi, C., Gussinyé, M., Carrascosa, A., & Vicens-Calvet, E. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501168 · Cited by 341
Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome
Gilling‐Smith, C., Story, H., Rogers, V., & Franks, S. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2321049.x · Cited by 301
Miller, K. K., Rosner, W., Lee, H., Hier, J., Sesmilo, G., Schoenfeld, D., Neubauer, G., & Klibanski, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030680 · Cited by 301 · cited 1×
“the two most sensitive and precise methods are radioimmunoassay (RIA) and tandem mass spectrometry. As direct assays of free testosterone are not reliable, free testosterone should not be measured but calculated from total testosterone and SHBG [”
MethodEarly metabolic abnormalities in adolescent girls with polycystic ovarian syndrome
Lewy, V. D., Danadian, K., Witchel, S. F., & Arslanian, S. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.109603 · Cited by 298
Cited by
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Asemi, Z., Samimi, M., Tabassi, Z., Shakeri, H., Sabihi, S.-S., & Esmaillzadeh, A. (2014) · Nutrition · doi:10.1016/j.nut.2014.03.008 · Cited by 136
(2012) · PubMed · Cited by 111
Reflections on inositol(s) for PCOS therapy: steps toward success
Nestler, J. E., & Unfer, V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1054802 · Cited by 106
“Indeed, although muscle and liver are insulin-resistant in women with PCOS, the ovaries retain normal insulin sensitivity [24–26].”
Background
Metadata
- Authors
- Harwood, K., Vuguin, P., & DiMartino-Nardi, J.
- Venue
- Hormone Research in Paediatrics
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 68
- Issue
- 5
- Pages
- 209-217
- ISSN
- 1663-2818 (ISSN-L)
- 1663-2826
- OpenAlex
- W2059899855
- Cited by
- 110
- References
- 14
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Approaches to the Diagnosis and Treatment of Polycystic Ovarian Syndrome in Youth. https://app.cochat.ai/papers/10.1159/000101538
- The paper
- Harwood, K., Vuguin, P., & DiMartino-Nardi, J. (2007). Current Approaches to the Diagnosis and Treatment of Polycystic Ovarian Syndrome in Youth. Hormone Research in Paediatrics. https://doi.org/10.1159/000101538
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.